SG11202109512SA - Leucine, acetyl leucine, and related analogs for treating disease - Google Patents

Leucine, acetyl leucine, and related analogs for treating disease

Info

Publication number
SG11202109512SA
SG11202109512SA SG11202109512SA SG11202109512SA SG11202109512SA SG 11202109512S A SG11202109512S A SG 11202109512SA SG 11202109512S A SG11202109512S A SG 11202109512SA SG 11202109512S A SG11202109512S A SG 11202109512SA SG 11202109512S A SG11202109512S A SG 11202109512SA
Authority
SG
Singapore
Prior art keywords
leucine
acetyl
treating disease
related analogs
analogs
Prior art date
Application number
SG11202109512SA
Inventor
Mallory Factor
Taylor Fields
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of SG11202109512SA publication Critical patent/SG11202109512SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202109512SA 2019-03-02 2020-03-02 Leucine, acetyl leucine, and related analogs for treating disease SG11202109512SA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962812987P 2019-03-02 2019-03-02
US201962842296P 2019-05-02 2019-05-02
US201962888894P 2019-08-19 2019-08-19
US201962895144P 2019-09-03 2019-09-03
PCT/IB2020/051767 WO2020178721A1 (en) 2019-03-02 2020-03-02 Leucine, acetyl leucine, and related analogs for treating disease

Publications (1)

Publication Number Publication Date
SG11202109512SA true SG11202109512SA (en) 2021-09-29

Family

ID=69845470

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109512SA SG11202109512SA (en) 2019-03-02 2020-03-02 Leucine, acetyl leucine, and related analogs for treating disease

Country Status (13)

Country Link
US (1) US20220142959A1 (en)
EP (1) EP3934637A1 (en)
JP (1) JP2022522819A (en)
KR (1) KR20210135272A (en)
CN (1) CN114040757A (en)
AU (1) AU2020231189A1 (en)
BR (1) BR112021017203A2 (en)
CA (1) CA3131948A1 (en)
IL (1) IL285870A (en)
MA (1) MA55199A (en)
MX (1) MX2021010568A (en)
SG (1) SG11202109512SA (en)
WO (1) WO2020178721A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
CN113348018A (en) * 2018-12-06 2021-09-03 内在生物技术有限公司 Deuterated analogs of acetyl-leucine
WO2022125304A1 (en) * 2020-12-10 2022-06-16 Texas Tech University System Bcaa-lowering compounds for prevention and/or treatment of alzheimer's disease and related disorders
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
TN2010000251A1 (en) * 2010-06-03 2011-11-11 Rekik Raouf N-ACETYL-DL-LEUCINE MEDICINAL NEURO AND RETINO PROTECTOR
KR20240068752A (en) 2010-06-25 2024-05-17 샤이어 휴먼 지네틱 테라피즈 인크. CNS delivery of therapeutic agents
US20140080885A1 (en) * 2012-09-13 2014-03-20 University Of South Florida (A Florida Non-Profit Corporation) Methods of treating traumatic brain injury
IL310508A (en) * 2016-04-19 2024-03-01 Intrabio Ltd Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
TN2016000259A1 (en) * 2016-06-27 2017-10-06 Rekik Raouf Salbutamol (albuterol) eye protective medicament.
SI3482754T1 (en) 2016-08-11 2021-04-30 Intrabio Ltd Pharmaceutical compositions and uses directed to lysosomal storage disorders
SI3416631T1 (en) * 2016-08-11 2019-09-30 Intrabio Ltd Therapeutic agents for neurodegenerative diseases

Also Published As

Publication number Publication date
MX2021010568A (en) 2021-11-12
AU2020231189A1 (en) 2021-09-30
US20220142959A1 (en) 2022-05-12
MA55199A (en) 2022-01-12
WO2020178721A1 (en) 2020-09-10
CA3131948A1 (en) 2020-09-10
EP3934637A1 (en) 2022-01-12
CN114040757A (en) 2022-02-11
JP2022522819A (en) 2022-04-20
BR112021017203A2 (en) 2021-12-14
KR20210135272A (en) 2021-11-12
IL285870A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
IL285870A (en) Leucine, acetyl leucine, and related analogs for treating disease
IL285782A (en) Compounds, compositions, and methods for the treatment of disease
IL279260A (en) Kdm1a inhibitors for the treatment of disease
EP3802539C0 (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
IL288958A (en) Exosomes for disease treatment
EP3922264A4 (en) Pharmaceutical composition for preventing, ameliorating or treating skin disease
IL288793A (en) Compounds for treating respiratory disease
EP4041248A4 (en) Modified oligonucleotides
EP3927375A4 (en) Compositions for disease treatment
PL3905977T3 (en) Systems for tissue treatment
IL286857A (en) Methods for the treatment of beta-thalassemia
IL286000A (en) Esketamine for the treatment of depression
EP3397267A4 (en) Peptides for the treatment of resorptive bone disease
FI4021505T3 (en) Medicament for treating infectious diseases
EP3963077A4 (en) Treatment for sod1 associated disease
GB201914296D0 (en) Treatment
IL267426A (en) Peptides for treating sjogren's syndrome
EP3577224A4 (en) Novel treatment for neat1 associated disease
IL291640A (en) 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease
GB201917691D0 (en) Compounds for treating respiratory disease
GB201908453D0 (en) Compounds for treating respiratory disease
GB201908451D0 (en) Compounds for treating respiratory disease
GB201911728D0 (en) Bacterial composistions for the treatment of disease
IL287840A (en) Treatment system
IL289440A (en) Process for the deprotection of oligonucleotides